patients with no episodes (HR 7.5; 95% CI 2.6, 22.0; p 0.01). CONCLUSIONS: Upper GI symptoms were significantly associated with poor adherence to and discontinuation of low-dose ASA. Strategies to help patients continue with low-dose ASA cardioprotection are warranted.
1
Solvay Pharmaceuticals Australia, Pymble, NSW, Australia, 2 Hi Connections Pty Ltd, Woden, ACT, Australia OBJECTIVES: To assess persistence to the combinations of dihydropyridine (DHP) calcium channel blockers (CCB) with an Angiotension Converting Enzyme (ACE) inhibitors or an Angiotension II Receptor Antagonist (A2RA), using PBS claims data provided by Medicare Australia. METHODS: This analysis is based on all scripts supplied to a one in ten sample of the Australian population drawn from de-identified Pharmaceutical Benefits payment records from January 2003 to December 2006. Initiation occurred with 2 consecutive months of an A2RA or an ACE combined with a DHP following at least 6 months without a DHP combination. Treatment cessation was 3 consecutive months of none or just one of the drugs making up the combination. Hazard ratios (HR) were derived and adjusted for patient age/ sex and initiating speciality. RESULTS: More than 17,500 Concessional patients, initiated on a DHP combined with an A2RA and more than 12,000 Concessional patients, initiated on a DHP combined with an ACE, had their persistence to the combination assessed. Median persistence [95% CI] differed between DHP combinations: Lercanidipine/ A2RA 23 months [22] [23] [24] [25] , Felodipine/A2RA 20 months [18] [19] [20] [21] [22] , Nifedipine/A2RA 17 months [16] [17] [18] , and Amlodipine/A2RA 14 months [13] [14] [15] . Using Lercanidipine/ A2RA as the reference (HR 1.00), patients were significantly more likely to cease the other combinations Felodipine/A2RA (8.7%), Nifedipine/A2RA (18.5%) and Amlodipine/A2RA (33.9%). Lercanidipine/ACE 24 months [22] [23] [24] [25] [26] , felodipine/ACE 21 months [19] [20] [21] [22] [23] [24] , nifedipine/ACE 16 months [14] [15] [16] [17] [18] , and amlodipine/ACE 15 months [14] [15] [16] [17] . Using Lercanidipine/ACE as the reference (HR 1.00), patients were more likely to cease the other combinations felodipine/ACE (7.2%), nifedipine/ACE (26.5%) and amlodipine/ACE (28.6%). CONCLUSIONS: In terms of optimal treatment persistence, lercanidipine seems to be the best DHP to combine with an A2RA or an ACE, while amlodipine seems to be the worst DHP to combine with an A2RA or an ACE.
PCV133 INFLUENCING FACTORS TO A GOOD ADHERENCE IN PATIENTS WITH CHRONIC HEART DISEASES
Origasa H, Sugiura S, Kumagai N, Sumi S University of Toyama School of Medicine, Toyama, Japan OBJECTIVES: To identify enhancing factors of the medication adherence using the data from a randomized trial of patients with chronic heart diseases. METHODS: We used the data from a randomized trial involving a total of 6967 patients with chronic heart diseases. This trial followed up them with an average of 5 years. Adherence rate was obtained by the division of a number of days to take a targeted medicine by 365 days each year for each patient. The targeted medicine was the one assigned by randomization. An overall adherence rate for each patient was defined by an average of annual adherence rates during the follow-up period. Good medication adherence was defined by the overall adherence rate of 80% or more. An adjusted odds ratio (OR) was used to show the degree of influence to a good adherence. RESULTS: Very high rate (94%) of good adherence was observed since the medication was an assigned drug in a randomized trial. Enhancing the odds of good adherence was women (OR 1.13, P 0.007), age (OR per 5-year increase 2.33, P 0.17), patients taking 5 or more medicines (OR 1.45, P 0.001), and good status on diet therapy (OR 1.95, P 0.001). Conversely, smokers decreased the adherence by 12% (P 0.008) and patients with previous stroke decreased the adherence by 29% (P 0.001). CONCLUSIONS: Patients taking many drugs or receiving diet therapy and women showed a statistically significant increase in the medication adherence.
PCV134 PREDICTORS OF NON-PERSISTENCE ON STATIN TREATMENTS IN ITALY: A RETROSPECTIVE
Cammarota S 1 , de Portu S 2 , Riegler S 3 , Citarella A 1 , Menditto E 1 , Mantovani LG 3 1 University of Naples, Naples, Italy, 2 University Federico II, Naples, Italy, 3 University of Naples, Federico II, Naples, Italy OBJECTIVES: The aim of this study was to estimate predictors of non-persistence with different statin treatments by the analysis of a general practitioner's (GP's) database covered a population of 144,000 inhabitants. METHODS: We analysed a cohort of adult patients ( 35 years) who newly initiated statin therapy between January 1,2005 and December 31,2005. The initiator status was confirmed by the absence of any statin prescription within 365 days prior to statin initiation. Persistence of statin utilization was analysed over 3 years follow-up period. The period covered by a prescription was defined by the number of tablets dispensed, based on one tablets per day. Treatment was considered discontinued if the interval between two prescriptions exceeded number of tablets prescribed, plus 60 days. Persistence was defined as the period from the first prescription date to the date of discontinuation. A Kaplan-Meier survival analysis and a multivariate Cox proportional hazards regression analysis was performed including in the model all covarietes (demographic characteristics, comorbilities, previous therapies) that may potentially confound the association between cohort and outcome. RESULTS: The final sample included 2382 patients (28.4% simvastatin; 7.3% fluvastatin; 13.4% pravastatin; 30.7% atorvastatin; 20.3% rosuvastatin). Only 23.2% of patients persisted for 3 years of therapy. Female gender and absence of diabetes comorbidity were the most significant predictors of early discontinuation. CONCLUSIONS: Further studies are required to evaluate whether these factors are related to persistence to treatment.
are related to persistence to treatment.
PCV135 HEALTH STATUS IN AN ARGENTINIAN POPULATION SURVEY : RESULTS FROM THE NATIONAL RISK FACTOR SURVEY
Augustovski FA 1 , Irazola V 1 , Kind P 2 1 Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 2 University of York, York, UK OBJECTIVES: To describe general population self-reported EQ-5D-VAS (VAS) and to explore its univariate relationships with sociodemographic (SDC) and health characteristics. METHODS: In 2005, the first "Risk Factors National Survey" was undertaken in Argentina, including 41,392 adults randomly selected from all Argentine provinces. Data were obtained on SDC, risk factors, and health status (EQ-5D and the general health question of SF-36). Mean and CI95% or median (IQR) are reported. All significant differences had p values 0.01. RESULTS: VAS had a mean of 75.35 (74.94 75.75 ) and a median of 80 (70-90) . General population mean and median social TTO based weights were 0.902 (0.898-0.905) and 1 (0.88-1). The range of reported limitations in each of the EQ-5D domains ranged from 2.9% in self-care to 30.9% in pain/discomfort. 44.9% had at least some limitation in one of the EQ-5D states, and 19.9% had a self-reported fair or poor health. VAS had a correlation of 0,49 with TTO based social weights. General Health was strongly correlated to VAS: those with excellent health had a mean of 91.76, while those with poor health had a mean of 39.43. Subjects that reported having a health problem in the last month had significantly less VAS than those who did not: 70.66 vs. 80.39. VAS was significantly related to cardiovascular risks factors (high blood pressure, high-cholesterol, overweight, high glycemia, low physical activity) except smoking. VAS was significantly lower in females, in the elderly, in subjects with less education, lower household income, and unemployed. CONCLUSIONS: VAS showed expected relations with SDC variables, with General Health, and in general, it showed to behave as expected with the presence of cardiovascular risk factors with the exception of smoking. This is one of the few general population surveys in Latin America that incorporated the EQ-5D tool to describe population health status.
PCV136 HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS
Oxford Outcomes, Oxford, Oxon, UK, 2 Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 3 Sanofi Aventis, Guildford, Surrey, UK OBJECTIVES: The study aimed to describe common adverse events associated with atrial fibrillation medications, as well as atrial fibrillation (AF) itself. The AF and adverse event descriptions were used to estimate societal utility values in the UK. METHODS: AF base health state descriptions were produced based on EQ-5D survey data with input from patients and clinicians. Adverse event descriptions were bolted to the EQ-5D derived base AF health states so that the associated disutility of specific treatment adverse events could be described. The health states described both paroxysmal/persistent and permanent AF along with 14 adverse events. Interviews with five AF experienced clinicians and six AF patients were carried out to assess the content and face validity of the health states. In total, 127 members of the UK general public valued the health states in a time trade-off (TTO) interview and ranking task. RESULTS: The study revealed the public preferences for atrial fibrillation and associated adverse event health states. There was a range of disutility reported for the adverse events from 0.01 for dizziness, 0.03 for rash, 0.08 for diarrhoea, 0.10 for hypothyroidism, to 0.17 for pulmonary complications. CONCLUSIONS: The study provides insight into the importance of atrial fibrillation treatment adverse events on patient's quality of life. As atrial fibrillation is a largely asymptomatic condition, the impacts of treatment adverse events on health related quality of life are amongst the most important factors considered in treatment decisions. The utility values collected in this study may prove useful in populating cost-effectiveness analyses.
PCV137 PREFERENCES OF PATIENTS, PHYSICIANS AND CAREGIVERS IN THE CHOICE OF ABDOMINAL AORTIC ANEURYSMS TREATMENT OPTIONS: THE PREFER STUDY
Scalone L 1 , Borghetti F 2 , Faggioli G 3 , Stella A 3 , Cortesi P 2 , Mantovani LG 4 1 University of Milan-Bicocca, Milan, Italy, 2 University of Milan, Milan, Italy, 3 Sant'Orsola Malpighi Hospital-University of Bologna, Bologna, Italy, 4 University of Naples, Federico II, Naples, Italy OBJECTIVES: Factors influencing preferences towards type of abdominal aortic aneurysm (AAA) have been scarcely investigated. The objective was to identify characteristics important for physicians, patients and their caregivers in the treatment of AAA. METHODS: We conducted a Discrete Choice Study involving AAA patients, their caregivers and experienced vascular surgeons. Participants self-completed questionnaires including 4-8 choice sets comparing pairs of options obtained from a factorial combination of 6 characteristics previously selected during a focus group and pilot study: type of anaesthesia (general vs. local); recovery time to everyday basic activities
